Search

Bimatoprost

It has the ability to reduce ocular hypotension, proving effective in conditions such as ocular hypertension and glaucoma. … [L6910] It was initially approved by the FDA in 2001 for ocular hypertension and later approved for hypothrichosis in 2008, as eyelash growth became a desirable adverse effect for patients using this drug

Dimenhydrinate

Dimehydrinate was first described in the literature in 1949, and patented in 1950. Early research into dimenhydrinate focused on its role as an antihistamine for urticaria; the treatment of motion sickness was an accidental discovery. Di...

Zuclopenthixol

It is an antagonist at D1 and D2 dopamine receptors. Major brands of zuclopenthixol are Cisordinol, Acuphase, and Clopixol. This drug is a liquid. This compound belongs to the thioxanthenes. … It is known that zuclopenthixol is metabolized by Cytochrome P450 2D6. Zuclopenthixol was approved for use in Canada in 2011, but is not approved for use in the United States.

Tocilizumab

[L12789] It was later approved by Health Canada on 30 April 2010. … [L40164] Subsequently, it was granted approval by Health Canada and the FDA in October [L43697] and December 2022, respectively.

Formoterol

[L10986] It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. … [A189528] A major clinical advantage of formoterol over other inhaled beta-agonists is its rapid onset of action (2-3 minutes), which is at least as fast as [salbutamol], combined with a long duration

Pramipexole

It was first approved by the FDA in 1997 [L5882]. … It is a _non-ergot dopamine agonist_ drug that is efficacious in treating various Parkinson's symptoms such as tremor, rigidity, and bradykinesia (slow movement) [A176867].

Bornaprine

Bevacizumab

[A286054] This off-label practice was formalized with the approval of Lytenava (bevacizumab-vikg in the US; bevacizumab gamma in the EU/UK), the first ophthalmic formulation of bevacizumab developed specifically … for intravitreal injection, which received European Commission and MHRA marketing authorization in 2024 and FDA approval on July 24, 2026 for the treatment of wet AMD.

Dimethicone

On skin, it is also observed to have moisturizing actions [L1771, L1773]. … It is used in a number of health and beauty products including hair care products such as shampoo, conditioner, leave-in conditioner, and de-tangling products.

Cabazitaxel

It was first approved by the FDA on June 17, 2010.[A260421] It was also approved by the EMA on March 17, 2011 [L47381] and Health Canada on December 17, 2019.[L47376]